India: Introduction Of Separate Regulatory Framework For Medical Devices

Last Updated: 12 October 2015
Article by Sunil Tyagi and Anu Chowdhry

In the Indo-U.S. Joint Statement released for the January 2015 visit of the U.S. President to India, bilateral collaboration in medical devices, pharmaceuticals, biotechnology and health-related information technology occupies prime position. Other healthcare agendas in the Joint Statement include completion of a Memorandum of Understanding among the Indian Ministry of Health & Family Welfare, the Indian Department of Biotechnology, the Indian Council of Medical Research, the All India Institute of Medical Sciences, the U.S National Institute of Health and National Cancer Institute and the upcoming completion of an Environmental Health, Occupational Health and Injury Prevention as well as a Control MoU between the U.S. Centerss for Disease Control and Prevention and the Indian Council for Medical Research.

India's total revenue potential for electronic medical devices is estimated at $ 6.4 billion for 2020. In an Executive Briefing in June, 2010, the United States International Trade Commission (USITC) noted that India's market for orthopaedic devices alone is expected to touch $600 million by 2015, attributable to an increasing elderly population that is projected to reach nearly 200 million by 2025. Healthcare companies in the U.S. have begun to tap into this market by forming strategic alliances with Indian entities. For instance in October 2013, Minneapolis-based Medtronic, the world's largest maker of heart rhythm devices, announced its entry in the kidney dialysis business in collaboration with India's Apollo Hospitals Enterprise Limited, and dedicated an investment of $24 million towards research, development and manufacturing in India. GE Healthcare (healthcare division of American conglomerate General Electric) has set up three manufacturing plants in the State of Karnataka, invested $500 million towards R&D in these facilities and has plans to introduce low-cost portable ultrasound machines in India. Predominant factors attracting such large-scale investment include focus on health insurance coverage and preventive care, rising demand for better medical infrastructure and specialized facilities, as well as growth of medical tourism. Despite the favorable outlook for India's medical device industry and the U.S. being considered a world leader in medical device innovation, foreign investors are yet to leverage these opportunities – a key reason being that although previous Foreign Direct Investment (FDI) policies permitted FDI in medical devices, separate norms for the sector had not been explicitly provided for.

Under the National Industrial Classification (NIC) 2008 (the industrial classification system for economic activities in India), pharmaceuticals and medical devices have been categorized as distinct industrial activities. The sector codes for "Manufacture of pharmaceuticals, medicinal, chemical, and botanical products" and "Manufacture of medical and dental instruments and supplies" are 2100 and 3250 respectively, where medical devices fall under "medical and dental instruments and supplies." Despite this distinct categorization and vast differences in nature and function between these two classes of goods, medical devices and pharmaceuticals were being treated as the same under the previous FDI regulations. A main reason was the Ministry of Health and Family Welfare, Government of India had classified 14 categories of medical devices as "drugs" under Section 3(b)(iv) of the Drugs and Cosmetics Act, 1940 (''Act''). As there is no separate legislation for regulating medical devices in India, their import, manufacture, distribution and sale is currently regulated under this Act read with the Drugs and Cosmetics Rules, 1945. (Non-notified [i.e. not specifically listed or categorized by the government] medical devices do not require registration, license, permission or No- Objection Certificates for import, manufacture, distribution and sale. This was clarified in an Order dated July 9, 2014 by Central Drug Standard Control Organization, Government of India). Notified medical devices were listed as being "drugs" and were hence considered a sub-set of pharmaceuticals by virtue of this legal fiction. In the absence of explicit FDI norms, medical devices (whether notified or non-notified) were subject to regulations that were in place for pharmaceuticals.

Shortly after the Government of India proposed amendments to the Consolidated Foreign Direct Investment Policy, 2014 ("FDI Policy") in its Cabinet Note in December, 2014, the Department of Industrial Policy and Promotion (DIPP) released Press Note No.2 (2015 Series) on January 6, 2015 (''Press Note 2''), thereby addressing the domestic industry's long-standing need of an FDI framework for medical devices which is independent of that governing pharmaceuticals. With effect from January 21, 2015, up to 100% FDI under the Automatic route is permissible in the medical device industry for both greenfield and brownfield projects. FDI in this sector has been restricted to manufacturing activities to boost local production, given that nearly 75% of the domestic market is presently dominated by imported medical devices. For the pharmaceutical industry, the present FDI Policy continues to permit up to 100% FDI under the Automatic route in greenfield projects and under the Government route (i.e. with prior approval of Foreign Investment Promotion Board) in brownfield projects, subject to sector-specific conditions. An important sector-specific condition for pharmaceuticals - brought into effect by Press Note 1 (2014 Series) dated January 8, 2014 - prohibits foreign companies from imposing non-compete clauses on Indian entities. To increase competition and access to low-cost drugs in the domestic market, non-compete clauses are permitted to be imposed only under "special circumstances" and with prior approval of FIPB. As pharmaceuticals and medical devices, which were clubbed together under the previous FDI Policy, the ban on non-compete clauses applied to both industries. Press Note 2 has altered the investment landscape by stipulating that sectoral conditions applicable to pharmaceuticals shall not be applicable to manufacturing of medical devices. As a result, foreign investors may now acquire up to 100% stake in existing manufacturing units under the Automatic route, as well as validly impose non-compete clauses on domestic targets without having to seek prior permission from FIPB. The American Chamber of Commerce has hailed the recent amendments to India's FDI Policy as conducive for American multinational corporations to undertake the manufacture of medical devices.

DIPP has sought to further ease the doing of business in India by linking sectors and activities in the FDI Policy to their corresponding codes under NIC–2008. Though NIC-2008 codes for the pharmaceutical sector have been incorporated in the FDI Policy through Press Note 1 (2015 Series) dated January 5, 2015, codes for medical devices are yet to be incorporated but likely to be soon included in the upcoming Consolidated FDI Policy of April, 2015.

The U.S. medical device trade association "AdvaMed" had stressed the need for separate legislative provisions for medical devices for sustaining long-term innovation and investment. The Medical Devices Regulation Bill, 2006 was an attempt in this direction but had been shelved. In parallel to the amendments in the FDI regime, the Department of Health and Family Welfare has now proposed a regulatory overhaul for medical devices, to be introduced as the Drugs and Cosmetics (Amendment) Bill, 2015 ("Bill") in the upcoming Budget Session of Parliament. The Bill proposes a separate Chapter IIA for regulating import, manufacture, sale and distribution of notified medical devices including penal provisions for contravention – thereby delineating legislative provisions on medical devices from drugs. Essential aspects including classification, standards, manufacturing, testing, distribution, labelling, packaging, essential requirements for quality, safety and performance, adverse events, post-marketing surveillance, exemptions, conditions of licenses, etc. shall be as prescribed. In comparison to the definition of medical devices contained in Press Note 2 (which is subject to a corresponding amendment to the Act), Section 3(v) of the Bill proposes a broader definition as including a wide range of instruments, whether used alone or in combination, for the purposes specified therein. To bring clarity as to what constitutes a medical device, both these definitions require to be aligned.

The absence of a clear description of "manufacturing" activities in the context of medical devices is a glaring omission in the present Act. Though Press Note 2 has not specified the scope of activities that qualify as "manufacturing" of medical devices, Section 3(t)(iii) of the Bill reveals the legislature's intention as including any process for designing, making, assembling, configuring, finishing, packing, sterilizing, labelling, refurbishing, or adapting of medical devices with a view to sell, stock or distribute or market them. This proposed definition excludes the assembling or adapting of a medical device (already approved for use for an individual patient) by registered medical practitioners from the purview of "manufacturing." Other salient features of the Bill include separate definitions for "investigational new medical device" (i.e. new device which is an object of clinical investigation or research or development involving one or more human participants to determine its safety and the effectiveness) as well as "new medical device" (i.e. a device which has not been approved by the Central Licensing Authority), and the establishment of a new Medical Devices Technical Advisory Board whose role would be to advise the Central and State Governments.

A series of other welcome measures have been introduced by the Central Drug Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, Government of India, to regulate the quality, safety and efficacy of medical devices, especially as it declared 2015 as the "Year for streamlining regulatory procedures without compromising patient safety." Regulations governing clinical trials in healthcare had long been a grey area for India. As per CDSCO's Order dated July 3, 2014, clinical trial procedures for medical devices shall be similar to the stringent provisions applicable to clinical trials of drugs/vaccines. The Drugs and Cosmetics (Fourth Amendment) Rules, notified in September, 2014, prescribe exhaustive labelling requirements and a five-year shelf-life rule for medical devices. The Rules also permit an extension of shelf-life subject to provision of satisfactory evidence justifying such extension. In December, 2014, CDSCO proposed comprehensive draft rules on good manufacturing practices and requirements of premises, plant and equipment for medical devices, in-vitro diagnostic kits and reagents, aimed at replacing Schedule M-III of the existing Rules. As FDI in manufacturing of medical devices is expected to increase, standardization of best practices is the need of the hour.

Incentives have also been provided under the direct tax regime to encourage scientific research and development (R&D), especially for businesses engaged in manufacturing activities. In May 2014, the Department of Scientific & Industrial Research (DSIR), Ministry of Science and Technology, issued new guidelines for approval of in-house R&D centers under Section 35(2AB) of the Income-Tax Act, 1961. Under this Section, where a company engaged in the business of bio-technology or in any business of manufacture or production of any defined article incurs any expenditure on scientific research on in-house R&D facilities approved by the prescribed authority (DSIR), it is allowed a deduction of a sum equal to two times the expenditure so incurred. This 200% deduction benefit is available subject to fulfilment of specific conditions and the assessee entering into an agreement with DSIR for cooperation in R&D. Nevertheless, it seems that the industry feels more fiscal incentives are required to position India as a global manufacturing hub for medical devices and generate cash flows for R&D. In this respect, the Federation of Indian Chambers of Commerce and Industry (FICCI) has proposed that the weighted deduction benefit be increased to 250% of approved expenditure incurred towards R&D for indigenous medical technology, and that manufacturers of indigenous medical devices be completely exempted from levy of Minimum Alternate Tax (MAT). Under Section 115(JB) of the IT Act, if the tax payable by any company (including a foreign company taxable in India) is less than 18.5% of its book profits, it is currently required to pay MAT which would be deemed as 18.5% of its book profits.

Indian industry has largely been biased towards importing finished medical devices due to these being chargeable with lesser import duty in many cases, as compared to import duty leviable on certain raw materials required for manufacturing medical devices. For example, importing titanium sheet/rod used for manufacturing implantable pacemakers attracts total import duty of 22.853% but importing the finished pacemaker itself attracts import duty of 12.034%. To address this imbalance, FICCI has called for no excise duty on medical devices that are manufactured in India (where imported raw material content is limited up to 50% of complete equipment cost) and no customs duty on raw materials imported by manufacturers of medical devices (where imported raw material content is limited up to 50% of complete equipment cost). Although the existing duty structure requires rationalization, relying on tariff barriers alone to promote local manufacturing may delay the entry of advanced medical technology and prove counter-productive for attracting foreign investment. Exempting or minimizing the service tax burden (currently levied at the rate of 12.36% on gross basis) for maintenance services with respect to medical devices has also been suggested by the industry. A recent news report summarized India's strengths in the medical device industry as having ''the right minds to produce low-cost gadgets, highly qualified doctors for advice, an ideal market that has a demand for these products and the capability to manufacture these products here.'' Though multinationals already produce medical devices in India, these legislative measures will create a favorable investment climate and make manufacturing a profitable enterprise.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions